Chronic lymphocytic leukemia · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ofatumumab monotherapy Variant #03 | — | R 512 332 | 28d | 29.4 mo | — | 6 | R 3 073 989 PFS proxy | 1 |
Alemtuzumab monotherapy Variant #03 | — | R 267 680 | 7d | ~15.0 mo | — | ~1 | ~R 267 680 PFS proxy · indirect | — |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | — | — | 24 | R 52 272 PFS proxy | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | 53.2 mo | — | 1 | — | 3 |
Observation Partial | — | — | — | 14.3 mo | — | — | — | 2 |
5 of 5 regimens shown